List of Tables

Sr. No	Name of the Table	Pg. No
1	Table 1.1BMI chart	3
2	Table 1.2Pharmacological Remedies	9
3	Table 1.3Prescription drugs for obesity	10
4	Table 1.4Herbal Remedies for the obesity	10
5	Table 1.5Marketed formulation for obesity	11
6	Table 1.6 List of the plant used in obesity	13
7	Table 2.1 Drug Treatment used for obesity	23
8	Table 2.1Herbal approach for the obesity	24
9	Table 2.3Methods of tablet praparation	33
10	Table 2.4Excipients used for tablet	34
11	Table 5Markers for HPLC	38
12	Table 1 Actives used for tablet preparation	53
13	Table 4.2Thin Layer Chromatography system	57
14	Table 4.3 Active concentration	59
15	Table 4.4Response variables	60
16	Table 4.5 Design Matrix	60
17	Table 4.6Desired values of variables	61
18	Table 4.7T-Test Table	70
19	Table 4.8Optimized Excipients concentration	71
20	Table 4.9Trials for optimization of mobile phase for HPLC method	77
21	Table 4.10Concentration of Gallic acid(GA) and oleanolic acid(OA)	77
22	Table 4.11HPTLC instrumentation	80
23	Table 4.12Various trials for HPTLC method optimization:	81
24	Table 4.13HPTLC Linearity table	82
25	Table 5.1Phytochemical Screening	93
26	Table 5.2 organoleptic evaluation	94
27	Table 5.3 Microbial Analysis	94
28	Table 5.4 TLC of extracts	94
29	Table 5.5 LOD results for extracts	95
30	Table 5.6Heavy metal results for extracts (from COA)	95
31	Table 5.7Calibration data for Gallic acid	95
32	Table 5.8Total phenolic content for all plant extracts	96
33	Table 5.9Calibration data for Tannin content	96
34	Table 5.10Total Tannin content	97
35	Table 5.11Absorbance of Quercetin	97
36	Table 5.12Total Flavanoid Content	98
37	Table 5.13Preformulation Data	98
38	Table 5.14 Tablet Formulation	99
39	Table 5.15Evalution of tablets	99

40	Table 5.16Stability Data	100
41	Table 5.17HPLC Method Parameter	100
42	Table 5.18Peak symmetry for Gallic acid and Oleanolic acid.	102
43	Table 5.19Interday and Intraday precision data	105
44	Table 5.20Recovery study of HPLC method	105
45	Table 5.21Robustness data for method validation	106
46	Table 5.22LOD & LOQ data	107
47	Table 5.23HPLC Chromatogram for developed polyherbal tablet	107
48	Table 5.24Quantification of markers in laboratory formulated tablet.	107
49	Table 5.25Optimized HPTLC condition	108
50	Table 5.26HPTLC Peak area for three marker	113
51	Table 5.27 Interday and Intraday precision data	115
52	Table 5.28HPTLC Robustness data	115
53	Table 5.29LOD and LOQ for all three markers	116
54	Table 5.30HPTLC Recovery data of all markers	116
55	Table 5.31Quantification of markers by HPTLC method	117
56	Table 5.32Molecular docking results of NPs and some standard drugs with alpha-amylase (6GXV)	119
57	Table 5.33Molecular docking results of NPs and some standard drugs with human gastric lipase	121
58	Table 5.34Molecular docking results of NPs and some standard drugs with human PPAR alpha (3VI8)	124
59	Table 5.35Molecular docking results of NPs and some standard drugs with leptin (1AX8)	129
60	Table 5.36Molecular docking results of NPs and some standard drugs with leptin (3V6O)	129
61	Table 5.37. Molecular docking results of NPs and some standard drugs with cannabinoid receptor type 1 (7V3Z)	130
62	Table 5.38Molecular docking results of NPs and some standard drugs with catalytic portion of human HMG-CoA reductase (1DQA)	132